EMEA-002489-PIP02-24 - paediatric investigation plan
rivoceranib
PIPHuman
Key facts
- Active Substance
- rivoceranib
- Therapeutic area
- Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Decision number
- P/0191/2024
- PIP number
- EMEA-002489-PIP02-24
- Pharmaceutical form(s)
- Tablet
- Condition(s) / indication(s)
- Treatment of hepatocellular carcinoma
- Route(s) of administration
- Oral use
- Contact for public enquiries
E-mail: elevar-medical@elevartherapeutics.com
Tel. +49 8374480- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date